Our focus: Achieving profound improvements in the evolution of radiotherapies.
While current and emerging TATs quickly shrink tumors, they are unlikely to achieve long-term survival for people who face metastatic cancer. Acute damage to healthy tissue combined with poor tolerability, clonal evolution, and delayed redosing leaves patients vulnerable to tumor regrowth and resistance, which contributes to poor survival. Realizing the full potential of radiopharma requires that we address the drivers of resistance to deliver complete and durable eradication.
Curadel’s Audacious Alpha™ technology prevents tumor resistance by addressing tumor heterogeneity while eliminating off-target binding to reduce the redosing interval.
Robust late-stage development and scale-up expertise
With a Phase 3 pivotal trial underway for a first-in-class zwitterionic drug for optical surgical navigation, Curadel has proven expertise in preparing pharmaceuticals for market readiness, including CMC, QMS, nonclinical studies, and clinical trial execution. Curadel has also developed integrated processes that significantly reduce time and funding required to reach registration.
